Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-09-01
2008-09-30
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S001530, C424S001690, C424S009340, C424S009351, C424S133100, C424S147100, C424S150100, C424S151100, C424S152100, C424S155100, C424S156100, C424S159100, C424S164100, C424S172100, C424S174100
Reexamination Certificate
active
07429381
ABSTRACT:
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
REFERENCES:
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4737453 (1988-04-01), Primus
patent: 4792521 (1988-12-01), Shochat
patent: 4818709 (1989-04-01), Primus et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 5078998 (1992-01-01), Bevan et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5128119 (1992-07-01), Griffiths
patent: 5183756 (1993-02-01), Schlom
patent: 5225541 (1993-07-01), Hackett et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5469854 (1995-11-01), Unger et al.
patent: 5502037 (1996-03-01), Kondratyer
patent: 5503987 (1996-04-01), Wagner et al.
patent: 5534254 (1996-07-01), Huston
patent: 5534756 (1996-07-01), Huston et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5716595 (1998-02-01), Goldenberg
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5851527 (1998-12-01), Hansen
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6077499 (2000-06-01), Griffiths
patent: 6096289 (2000-08-01), Goldenberg
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6126916 (2000-10-01), McBride
patent: 6187284 (2001-02-01), Griffiths
patent: 6962702 (2005-11-01), Hansen
patent: 7074405 (2006-07-01), Hansen
patent: 2002/0006379 (2002-01-01), Hansen et al.
patent: 2003/0113333 (2003-06-01), Rossi et al.
patent: 2003/0162709 (2003-08-01), Rossi et al.
patent: 0263046 (1988-04-01), None
patent: 0419387 (1991-03-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0623675 (1994-11-01), None
patent: 921782 (1992-12-01), None
patent: 03173900 (1991-07-01), None
patent: WO 9604313 (1996-02-01), None
patent: WO 97/41898 (1997-11-01), None
patent: WO 9808875 (1998-03-01), None
patent: WO 99/66951 (1999-12-01), None
patent: WO 00/34317 (2000-06-01), None
Rader et al, Proc. Natl. Acad. Sci. USA, vol. 95, 8910-8915, 1998.
Rudikoff et al, Proc. Natl. Acad. Sci. USA, vol. 79, 1979-1983, 1982.
Boisferon, Hillairet de et al., “Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens” Bioconjugate Chem. 2000 11, 252-460.
Pluckthun et al., “New protein egineering approaches to Multivalent and bispecific antibody fragments,” Immunotechnology 3 (1997) 83-105.
Pack, et al., “Tetravalent Miniantibodies with High Avidity Assembling inEscherichia coli,” J. Mol. Biol. (1995) 246, 28-34.
Sharkey et al., “A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody,” Cancer Research 63, 354-363 (Jan. 15, 2003).
Arano, Yasushi, et al., “Reassessment of Diethylenetriaminepentaacetic Acid (DTPA) as a Chelating Agent for Indium-111 Labeling of Polypeptides Using a Newly Synthesized monoreactive DTPA Derivative,” J. Med. Chem. vol. 39, pp. 3451-3460, 1996.
Barmas, A., et al., “Two-Step Strategies for the Diagnosis and Treatment of Cancer with Bioconjugates,” Antibody, Immunoconjugates, Radiopharm., vol. 5, No. 4, pp. 385,395, 1992.
Bos, Ebo S., et al., “in Vitro Evaluation of DNA-DNA Hybridization as a Two-Step Approach in Radioimmunotherapy of Cancer,” Cancer Research, vol. 54, pp. 3479-3486, 1994.
Barbet, et al., “Radioimmunotherapy of LS174T Coloon carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA X Anti-lindium-DTPA Bispecific Antibody,” J. Nucl. Med., vol. 38, p. 7, 1997.
Greenwood, F. C., et al., “The Preparation of 1311-Labelled Human Growth Hormone of High Specific Radioactivity,” The Biochemical Journal, vol. 89, pp. 114-123; 1963.
Kaneko, T., “New Hydrazone Derivative of Adriamycin and Their Immunoconjugates—a Correlation between Acid Stability and Cytotoxicity,” J. Bioconjugate Chem., vol. 2, No. 3, pp. 133-141, 1991.
Losman, M. J., et al., “Generation and Monitoring of Cell Lines Producing Humainzed Antibodies,” Clin. Cancer Research, vol. 5, (10 Suppl.) pp. 3101s-3105s, 1999.
Penefsky, Harvey S., “A Centrifuged-Column Procedure for the Measurement of Ligan Binding by Beef Heart F,” Methods in Enzymology, Part G, vol. 56, pp. 527-530, 1979.
Wang, Shing-Ming, et al., “Specific Activation of Glucuronide Prodrugs by Antibody-targeted Enzyme Conjugates for Cancer Therapy,” Cancer Res., vol. 52, pp. 4484-4491, 1992.
De Jonge, Jan, et al., “Production and Characterization of Bispecific Single-Chain Antibody Fragments,” Molecular Immunology, vol. 32, No. 17/18, pp. 1405-1412, 1995.
Boden, V., et al., “Preliminary Study of the Metal Binding Site of an Anti-DTPA-Indium Antibody by Equilibrium Binding Immunoassays and Immobilized Metal Ion Affinity Chromatography,” Bioconjugate Chem., vol. 6, pp. 373-379, 1995.
Gold et al., Cancer Research, 50 6405-6409, 1990.
Van Spriel, et al., “Immunotherapeutic Perspective for Bispecific antibodies” Immunology Today, 21, 391-396, 2000.
Kontermann, Roland E., “Interacellular and Cell Surface Displayed single-chain Diabodies” Journal of Immunological Methods 226 (1999) 179-188.
Dubel, S., “Reconsittution of human pancreatic RNase from two separate fragments fused to different single chain antibody fragments: on the way to binary immunotoxins” Tumor Targeting (1999) 4, 37-46.
Hayden, M. “Single-chain mono-and bispecific antibody derivatives with novel biological properties and anatitumour activity from a COS cell transient expression system” Therapeutic Immunology, 1994, 1, 3-15.
Yang, “A Genetically Engineered Single-Chain FV/TNF Molecule Possesses the Anti-Tumor Immunoreactivity of FV as well as the Cytotoxic Activity of Tumor Necrosis Factor” Molecular Immunology vol. 32, No. 12, pp. 873-881, 1995 XP 000653177.
G. Hawkins et al., “Delivery of Radionuclides to Pretargeted Monoclonal, Antibodies Using Dihydrofolate Reductase and Methotrexagte in an Affinity System”, Cancer Research, May 1993, pp. 2368-2373, vol. 53.
David A. Goodwin et al., “Pre-Targeted Immunoscintigraphy of Murine Tumors with Indiums-111-Labeled Bifunctional Haptens”, J. Nucl., Med., 1998, pp. 226-234, vol. 29.
Dwight R. Stickney et al., “Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma”, Cancer Research, Dec. 15, 1991, pp. 6650-6655, vol. 51.
Emmanuel Gautherot et al., “Therapy for Colon Carcinoma Xengografts with Bispecific Antibody-Targeted Iodine-131-Labeled Vivalent Hapten”, Cancer Supplement, 1997, pp. 2618-2623, vol. 80.
J. Barbet et al., “Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111-Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium”, The Journal of Nuclear Medicine, Jul. 1998, vol. 39, No. 7.
Marion H.G.C. Kranenborg et al., “Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting o
Griffiths Gary L.
Hansen Hans J.
Leung Shui-on
McBride William J.
Qu Zhengxing
Immunomedics Inc.
Nakashima Richard A.
Saunders David A
LandOfFree
Production and use of novel peptide-based agents for use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production and use of novel peptide-based agents for use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production and use of novel peptide-based agents for use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3973051